John S. McBride

CIK: 0001618251

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (33.3%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ELDN

Eledon Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

ELDN
Eledon Pharmaceuticals, Inc.
Jan 10, 2026
Exercise(M)
Direct
3.4K shares-
ELDN
Eledon Pharmaceuticals, Inc.
Jan 10, 2025
Award(A)
Stock Option (right to buy)
Direct
30.9K shares-
ELDN
Eledon Pharmaceuticals, Inc.
Jan 10, 2025
Award(A)
Restricted Stock Units
Direct
3.4K shares-

		Type	Shares	Price		Ownership
Jan 10, 2026	ELDN Eledon Pharmaceuticals, Inc.	Exercise(M)	3,430	-	$0	Direct
Jan 10, 2025	ELDN Eledon Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	30,870	-	-	Direct
Jan 10, 2025	ELDN Eledon Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	3,430	-	-	Direct

1-3 of 3 transactions

About McBride John S.

McBride John S. (SEC CIK 0001618251) files insider reports with the SEC as Director of Eledon Pharmaceuticals, Inc. (ELDN).

Signal8 holds 2 ownership filings by McBride John S., all Form 4s, filed between Jan 13, 2025 and Jan 16, 2026. Those filings report 3 transactions, from Jan 10, 2025 to Jan 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on McBride John S.'s filings is in IRVINE, CA.

Recent filings by McBride John S.

Jan 10, 2026: Option exercise of ELDN shares (Form 4, code M).
Jan 10, 2025: Grants or awards of ELDN derivative securities (2 lines, Form 4, code A).

Other insiders filing for Eledon Pharmaceuticals, Inc. (ELDN)

Gros David-Alexandre C, Chief Executive Officer
Perrin Steven, President
Hillson Jan, Director
Kirk Allan, Director
Katkin Keith, Director
Lee June, Director

How to read Form 4 transaction codes